Xeltis Appoints Nobel Prize Winner Prof. Jean-Marie Lehn to Its Advisory Board

  Xeltis Appoints Nobel Prize Winner Prof. Jean-Marie Lehn to Its Advisory
  Board

Business Wire

ZURICH -- January 8, 2014

Xeltis,  a privately held medical device company dedicated to transforming
standards of care in heart valve replacement and vascular surgery, has
announced that Prof. Jean-Marie Lehn, Ph.D., has joined its scientific
advisory board. Lehn is co-winner of the 1987 Nobel Prize in Chemistry for his
work in supramolecular chemistry, the science that Xeltis used as the basis
for its self-healing implant technology. He joins the company’s scientific
advisory board in the midst of its first-in-human feasibility study at the
prestigious Bakoulev  Center for Cardiovascular Surgery in Moscow.

Prof. Lehn is recognized as a pioneer in supramolecular chemistry, a term he
first coined. Using proprietary technology based on his Nobel-Prize winning
science, Xeltis produces biodegradable matrices designed to stimulate and
guide the body’s natural healing response without the need for stem cells,
growth factors or animal-based tissue. The company’s feasibility study is
focused on the implantation of a conduit designed to address a specific heart
defect in children. Xeltis’ first product will ultimately be a full
replacement valve for this population.

“I am very gratified to see the science we developed many years ago applied to
the field of medicine, especially among a vulnerable patient population with
no current long-lasting treatment alternatives,” said Prof. Lehn. “If the
concept is proven in clinical studies, Xeltis may make it possible for these
children to be treated with only one surgery in their lifetimes.”

Prof. Lehn is currently active on a number of scientific advisory boards,
including those of Xeltis, Novartis Venture Fund and Reliance Industries Ltd.
He is the director of the Supramolecular Chemistry Laboratory at the Institute
of Supramolecular Science and Engineering in Strasburg, France, and until
recently headed the chemistry laboratory at the Collège de France. Prof. Lehn
has also served as a visiting professor at a number of prestigious
institutions, including Harvard University, E.T.H. in Zürich and the
Universities of Oxford, Cambridge, Barcelona and Frankfurt. His work has been
published in hundreds of articles in peer-reviewed chemistry literature. He is
a member of several National Academies of Sciences including those of France,
the United States and Russia as well as the recipient of countless prizes and
distinctions.

“Prof. Lehn is an extraordinary scientist who has made our work today
possible,” said Laurent Grandidier, chief executive officer, Xeltis. “We
welcome his unique perspectives and his passion as we begin to investigate our
technology’s use in the clinical environment.”

About Xeltis

Founded in Zurich in 2006, Xeltis is a privately held medical device company
dedicated to transforming standards of care in heart valve replacement and
vascular surgery. Using proprietary technology based on Nobel-prize winning
science, Xeltis produces biodegradable matrices designed to stimulate and
guide the body’s natural healing response without the need for stem cells,
growth factors or animal-based tissue. For more information, visit
www.xeltis.com.

Contact:

Nobles Global Communications
Laura Nobles
+1 310-795-0497
laura@noblesgc.com